Celltrion Healthcare Co., Ltd.
091990
株式のランク
#2133
Celltrion Healthcare Co., Ltd. is a global pharmaceutical company focused on... Celltrion Healthcare Co., Ltd. is a global pharmaceutical company focused on the development, manufacturing, and distribution of biosimilar and biological therapeutic agents for patients around the globe. Its product lineup includes Remsima, a monoclonal antibody biosimilar used to treat various inflammatory and autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, Crohn's disease in both adults and children, psoriasis, and psoriatic arthritis. Another significant offering, Truxima, targets conditions like lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis, microscopic polyangiitis, and rheumatoid arthritis. Herzuma is prescribed for metastatic breast cancer, early-stage breast cancer, and metastatic gastric cancer. Additionally, Remsima SC provides a treatment option for rheumatoid arthritis. Founded in 1999, the enterprise was initially known as Nexol, Inc. before rebranding to Celltrion Healthcare Co., Ltd. in March 2009. The firm's corporate headquarters are situated in Incheon, South Korea.
株価
$57.75
最終同期: 2024-01-11
時価総額
$9.42B
変化（1日）
-0.25%
変化（1年）
0.00%
国
KR
取引 Celltrion Healthcare Co., Ltd. (091990)
カテゴリー
Healthcare
Celltrion Healthcare Co., Ltd.（091990）の配当履歴
Celltrion Healthcare Co., Ltd.（証券コード：091990）は合計で1回の配当を行いました。
すべての配当の合計（株式分割調整済み）は：$130.00
配当利回り（TTM）：0.0017
すべての配当の合計（株式分割調整済み）は：$130.00
配当利回り（TTM）：0.0017
2022から2026までのCelltrion Healthcare Co., Ltd.（091990）の配当履歴
年間配当支払い
| 年 | 配当（株式分割調整済み） | 変化 |
|---|---|---|
| 2026 (TTM) | $130.00 | 0.00% |
| 2022 | $130.00 | 0.00% |
すべての配当支払いの一覧
| 年 | 配当 | 変化 |
|---|---|---|
| 2026 (TTM) | $135.20 | 0.00% |
| 2022 | $135.20 | 0.00% |
同業他社や競合企業の配当履歴
| 企業 | 配当支払い回数 | 国 |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 67.00% |
AU
|
|
| 30.00% |
BE
|
|
| 0.00% |
NL
|
